MacroGenics Inc. (NASDAQ:MGNX)‘s stock had its “buy” rating restated by stock analysts at Roth Capital in a research note issued on Wednesday.

A number of other analysts have also weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $52.00 price objective on shares of MacroGenics in a research note on Thursday, November 3rd. Zacks Investment Research raised shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Wednesday, July 20th. Cowen and Company started coverage on shares of MacroGenics in a report on Wednesday, September 7th. They set an “outperform” rating on the stock. Citigroup Inc. downgraded shares of MacroGenics from a “buy” rating to a “neutral” rating and increased their price target for the stock from $27.00 to $32.00 in a report on Thursday, August 4th. Finally, TheStreet raised shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $36.57.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ:MGNX) opened at 28.92 on Wednesday. The stock’s market cap is $1.01 billion. MacroGenics has a 1-year low of $14.84 and a 1-year high of $36.11. The company’s 50 day moving average is $26.50 and its 200-day moving average is $26.96.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported ($0.97) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by $0.17. The business earned $3.30 million during the quarter, compared to analyst estimates of $12.45 million. MacroGenics had a negative return on equity of 16.99% and a negative net margin of 55.01%. The firm’s revenue was down 77.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.46) EPS. Equities research analysts forecast that MacroGenics will post ($1.57) earnings per share for the current fiscal year.

In other news, VP Lynn Cilinski sold 6,231 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $29.28, for a total value of $182,443.68. Following the completion of the sale, the vice president now directly owns 8,154 shares in the company, valued at $238,749.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Jon Marc Wigginton sold 10,000 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $29.34, for a total transaction of $293,400.00. Following the completion of the sale, the chief marketing officer now owns 10,000 shares of the company’s stock, valued at $293,400. The disclosure for this sale can be found here. 6.78% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of MGNX. American International Group Inc. boosted its stake in shares of MacroGenics by 0.4% in the second quarter. American International Group Inc. now owns 18,352 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 65 shares during the period. ProShare Advisors LLC boosted its stake in shares of MacroGenics by 0.7% in the second quarter. ProShare Advisors LLC now owns 29,614 shares of the biopharmaceutical company’s stock worth $799,000 after buying an additional 200 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of MacroGenics by 1.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,981 shares of the biopharmaceutical company’s stock worth $431,000 after buying an additional 253 shares during the period. TIAA CREF Investment Management LLC boosted its stake in shares of MacroGenics by 0.3% in the third quarter. TIAA CREF Investment Management LLC now owns 99,527 shares of the biopharmaceutical company’s stock worth $2,977,000 after buying an additional 257 shares during the period. Finally, Teacher Retirement System of Texas boosted its stake in shares of MacroGenics by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 466 shares during the period. Institutional investors and hedge funds own 81.81% of the company’s stock.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

5 Day Chart for NASDAQ:MGNX

Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.